Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth J Davis

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
International Journal of Surgical Oncology|January 25, 2021
Inadvertent Inguinal Sarcoma Excision during Hernia Surgery: Outcomes, Gender Analysis, and PreventionJoshua M Lawrenz, James P Norris, Marcus C Tan, et al.
Medical Oncology (Northwood, London, England)|August 22, 2018
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcomaAlexandra Pender, Elizabeth J Davis, Dharmisha Chauhan, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2015
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcomaElizabeth J Davis, Rashmi Chugh, Lili Zhao, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.
Genes|November 11, 2022
The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective AnalysisLawrence Liu, Carina Dehner, Nikhil Grandhi, et al.
Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
JAMA Oncology|March 25, 2021
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected MelanomaJ Randall Patrinely, Rebecca Johnson, Aleigha R Lawless, et al.
Journal of Adolescent and Young Adult Oncology|February 1, 2023
Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working GroupSusan L Whiteway, Aaron R Weiss, Safia K Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2024
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid HemangioendotheliomaScott M Schuetze, Karla V Ballman, Rachel Heise, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
International Journal of Surgical Oncology|January 25, 2021
Inadvertent Inguinal Sarcoma Excision during Hernia Surgery: Outcomes, Gender Analysis, and PreventionJoshua M Lawrenz, James P Norris, Marcus C Tan, et al.
Medical Oncology (Northwood, London, England)|August 22, 2018
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcomaAlexandra Pender, Elizabeth J Davis, Dharmisha Chauhan, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2015
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcomaElizabeth J Davis, Rashmi Chugh, Lili Zhao, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.
Genes|November 11, 2022
The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective AnalysisLawrence Liu, Carina Dehner, Nikhil Grandhi, et al.
Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
JAMA Oncology|March 25, 2021
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected MelanomaJ Randall Patrinely, Rebecca Johnson, Aleigha R Lawless, et al.
Journal of Adolescent and Young Adult Oncology|February 1, 2023
Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working GroupSusan L Whiteway, Aaron R Weiss, Safia K Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2024
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid HemangioendotheliomaScott M Schuetze, Karla V Ballman, Rachel Heise, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Pageof 5